Avapritinib

Major

Avapritinib Fosphenytoin Cerebyx Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Idelalisib Zydelig Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Imatinib Gleevec Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Indinavir Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Influenza Virus Vaccine, Live An increased risk of infection by the live vaccine Details Avapritinib Isavuconazole Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Isavuconazonium Cresemba Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Itraconazole Sporanox Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Ivosidenib Tibsovo Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Ketoconazole Extina Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Larotrectinib Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Avapritinib Lefamulin Xenleta Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Lenacapavir Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Avapritinib Lesinurad Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Letermovir Prevymis Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Lonafarnib Zokinvy Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Avapritinib Lopinavir Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Lorlatinib Lorbrena Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Lumacaftor Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Mifepristone Korlym Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Mitapivat Aqvesme Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Mitotane Lysodren Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Modafinil Provigil Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Nafcillin Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Nefazodone Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Nelfinavir Viracept Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Netupitant Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Nilotinib Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Nirogacestat Ogsiveo Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details Avapritinib Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Avapritinib Paritaprevir Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Pexidartinib Turalio Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Phenobarbital Fidoquel Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Phenytoin Dilantin Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Avapritinib Posaconazole Noxafil Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Primidone Mysoline Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Avapritinib Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details